Alzheimer's disease: the first treatments are a game-changer

Alzheimer's disease: first treatments change the game

September 6, 2025

By Hugo Jalinière THE Subscribers

While research has long been held in check, the approval of the first drugs capable of countering the progression of Alzheimer's disease has revived all expectations.

Donanemab

Donanemab reduces amyloid plaques in Alzheimer's disease.

Photo by WLADIMIR BULGAR/SCIENCE PHOTO LI / WBU / Science Photo Library via AFP

This article is taken from the monthly Sciences et Avenir n°943, dated September 2025.

Let's face it: in twenty-five years, Alzheimer's disease is the pathology for which medical research has recorded the highest failure rate. In 2014, an American team calculated that 99.6 of the approximately 500 clinical trials conducted since 2002 had resulted in the molecule being tested being abandoned.

Antibody Tau protein Alzheimer's disease

en_USEnglish